↑ Grab this Headline Animator

In the U.S. 40000 People Died from Metastatic Breast Cancer in 2003...

Research and Markets (http://www.researchandmarkets.com/reports/c27951) has announced the addition of Profiles in Metastatic Breast Cancer to their offering.



In 2003, approximately 40,000 deaths in the United States were attributed to breast cancer. While significant therapeutic advances for early-stage disease have emerged in recent years, an estimated 30% to 40% of all patients (in Western countries) ultimately develop metastatic breast cancer (MBC). Median survival for MBC patients is estimated at an all too brief two years, underscoring tremendous unmet need among the MBC population.



Profiles in Metastatic Breast Cancer spotlights for drug developers potential opportunities for clinical and commercial advances in MBC drug development. These potential opportunities are identified through insights derived from:



A qualitative online discussion among key opinion leaders

A quantitative survey and conjoint exercise completed by 100 community-based oncologists in the United States



This study will help clients understand therapeutic unmet needs and the product attributes and levels of performance that drive physician preference and prescribing behavior. Further, the study looks prospectively at promising novel therapeutic targets and investigational agents for MBC. Taken together, the components of Profiles in Metastatic Breast Cancer form an essential analytical tool for any organization contemplating the development, acquisition, or launch of an agent aimed at this vastly underserved patient population.



Key Points:

While community oncologists and KOLs provided similar responses in ranking toxicities from the physician perspective, the two groups diverged noticeably in ranking toxicities from the patient perspective

Although one of the longstanding assumptions of drug development is that oral administration is almost always preferable to IV/injectable administration, a tradeoff analysis among a large body of practicing oncologists here reveals that oral administration is of minimal importance



For more information visit http://www.researchandmarkets.com/reports/c27951



Laura Wood

Senior Manager

Research and Markets

email protected from spam bots

Fax: +353 1 4100 980

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Paperstreet | Web Site | content management system |

---

4872 readers online...

, Local News